7-11 boulevard Haussmann
33 1 53 83 08 41
Impiegati a tempo pieno: 22
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Philippe Pouletty M.D., Ph.D.||Founder & Director||N/D||N/D||1958|
|Mr. Marc M. P. de Garidel M.B.A.||CEO & Interim Chair of Board||N/D||N/D||1958|
|Mr. Didier Blondel||EVP, CFO & Board Sec.||N/D||N/D||N/D|
|Ms. Raquel Lizarraga||Investor Relations Mang.||N/D||N/D||N/D|
|Ms. Regina Jehle||VP of Communications||N/D||N/D||N/D|
|Anne Pascard||HR Mang.||N/D||N/D||N/D|
|Mr. Pierre Courteille M.B.A.||Chief Bus. Officer||N/D||N/D||N/D|
|Mr. Sheldon Sloan||Chief Medical Officer||N/D||N/D||N/D|
|Mr. Michael Ferguson B.S., M.B.A.||Chief Commercial Officer||N/D||N/D||N/D|
|Mr. Paul Gineste||VP Clinical Operations||N/D||N/D||N/D|
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that modulate the body's natural immune system to treat patients with chronic inflammatory, infectious, and cancer diseases. The company's products include obefazimod that is in Phase III clinical trials for the treatment of ulcerative colitis; Phase IIb clinical trials for the treatment of Crohn's Disease; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and in a pre-clinical trial for the treatment of Respiratory Syncytial Virus. It also develops ABX 196, an immune enhancer candidate that is in Phase 2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue, influenza, and respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
L'ISS Governance QualityScore di ABIVAX Société Anonyme al 1 giugno 2023 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 7; retribuzione: 10.